Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 478
Filter
1.
Epilepsy Behav ; 113: 107551, 2020 12.
Article in English | MEDLINE | ID: mdl-33246234

ABSTRACT

OBJECTIVE: Due to supply shortage, amobarbital, the traditional anesthetic agent in Wada testing, was replaced by methohexital in many epilepsy centers. This study aimed to compare the two barbiturates to identify possible advantages or disadvantages of methohexital as compared to amobarbital with regard to the adequacy of language and memory testing during the Wada test. METHODS: Data from 75 patients with temporal lobe epilepsy who underwent bilateral Wada tests using either amobarbital (n = 53) or methohexital (n = 22) as part of presurgical work-up were analyzed retrospectively. The two subgroups were compared regarding hemispheric language and memory lateralization results and Wada testing characteristics, and the adequacy of language and memory testing was assessed. RESULTS: We observed shorter durations of motor-, speech-, and EEG recovery after each injection in patients receiving methohexital compared to amobarbital. In addition, significantly more items could be presented during effective hemispheric inactivation in the methohexital group. Moreover, significant correlations of Wada memory scores with standard neuropsychological memory test scores could be found in the methohexital group. SIGNIFICANCE: Our findings confirm that methohexital is not only equally suitable for Wada testing but has several advantages over amobarbital. Wada testing can be performed more efficiently and under more constant hemispheric inactivation using methohexital. Furthermore, the adequacy of language and memory testing during the Wada test might be affected by the anesthetic agent used.


Subject(s)
Amobarbital/pharmacology , Anesthetics/pharmacology , Epilepsy, Temporal Lobe/diagnosis , Functional Laterality , Hypnotics and Sedatives/pharmacology , Memory/drug effects , Methohexital/pharmacology , Speech/drug effects , Adolescent , Adult , Anesthetics/therapeutic use , Cerebrum/drug effects , Cerebrum/physiopathology , Child , Epilepsy, Temporal Lobe/physiopathology , Epilepsy, Temporal Lobe/surgery , Female , Humans , Language , Language Tests , Male , Memory/physiology , Middle Aged , Retrospective Studies , Speech Reception Threshold Test , Young Adult
2.
Vet Surg ; 48(1): 70-78, 2019 Jan.
Article in English | MEDLINE | ID: mdl-30367699

ABSTRACT

OBJECTIVE: To determine the influence of propofol or methohexital, with and without doxapram, on the examination of laryngeal function in dogs. STUDY DESIGN: Experimental study. ANIMALS: Forty healthy dogs randomly assigned to 4 groups: propofol with saline (n = 10), propofol with doxapram (n = 10), methohexital with saline (n = 10), or methohexital with doxapram (n = 10). METHODS: Propofol and methohexital were administered to effect. Investigators examined laryngeal function (initial) simultaneously with video laryngoscopy. Doxapram or saline was administered, and laryngeal function was reevaluated (second). Laryngeal motion, quality of laryngeal exposure, and the degree of swallowing, laryngospasm, and jaw tone were scored at each evaluation. Adverse events were recorded. Initial and second videos were evaluated by a masked observer, and still images obtained from both evaluations were evaluated for change in rima glottidis size by 2 masked observers. RESULTS: Administration of doxapram and saline was delayed with propofol (P = .001). Laryngeal function did not differ between dogs receiving propofol or methohexital, irrespective of doxapram administration. Doxapram improved breathing scores in both groups (P < .001). Jaw tone increased with propofol during the second evaluation (P = .049). Swallowing was more prevalent at initial examination (P = .020). Methohexital resulted in an increased heart rate (P < .001) compared with propofol. Twenty-five percent of dogs receiving methohexital developed seizure-like activity (n = 5/20). CONCLUSION: Evaluation of laryngeal function did not differ between healthy dogs anesthetized with propofol or methohexital. Methohexital provided shorter examination times with less jaw tone but was associated with adverse events. CLINICAL SIGNIFICANCE: This study provides evidence to recommend propofol over methohexital as an induction agent for laryngeal function examination.


Subject(s)
Anesthetics, Intravenous/pharmacology , Dogs/physiology , Doxapram/pharmacology , Larynx/physiology , Methohexital/pharmacology , Propofol/pharmacology , Respiratory System Agents/pharmacology , Animals , Female , Larynx/drug effects , Male , Physical Examination/veterinary , Random Allocation , Treatment Outcome
3.
Clin Imaging ; 51: 155-159, 2018.
Article in English | MEDLINE | ID: mdl-29501883

ABSTRACT

A middle-aged patient underwent staged endovascular embolization of a Spetzler-Martin grade V right parietal arteriovenous malformation(AVM).In the fifth endovascular embolization, after methohexital 10 mg injection into a right posterior choroidal artery feeding the AVM nidus, there was an immediate change in the electroencephalogram (EEG) with simultaneous loss of motor evoked potentials (MEPs) in the bilateral upper and lower extremities and a delayed change in somatosensory evoked potential responses (SSEPs). No embolization was made and procedure was terminated. This case demonstrates the utility of intraoperative neurophysiologic monitoring (IONM) with pharmacologic provocative testing in predicting and mitigating the risks prior to the proposed embolization.


Subject(s)
Anesthetics, Intravenous , Arteriovenous Fistula , Embolization, Therapeutic/methods , Intracranial Arteriovenous Malformations/therapy , Methohexital , Posterior Cerebral Artery/abnormalities , Anesthetics, Intravenous/pharmacology , Arteriovenous Fistula/physiopathology , Brain , Electroencephalography , Evoked Potentials, Motor , Evoked Potentials, Somatosensory , Humans , Intracranial Arteriovenous Malformations/physiopathology , Intraoperative Neurophysiological Monitoring/methods , Methohexital/pharmacology , Middle Aged
4.
Am J Emerg Med ; 35(8): 1101-1105, 2017 Aug.
Article in English | MEDLINE | ID: mdl-28330689

ABSTRACT

BACKGROUND: Propofol is a preferred agent for many pediatric sedation providers because of its rapid onset and short duration of action. It allows for quick turn around times and enhanced throughput. Occasionally, intravenous (IV) methohexital (MHX), an ultra-short acting barbiturate is utilized instead of propofol. OBJECTIVE: Describe the experience with MHX in a primarily propofol driven outpatient sedation program and to see if it serves as an acceptable alternative when propofol is not the preferred pharmacologic option. METHODS: Retrospective chart review from 2012 to 2015 of patients receiving IV MHX as their primary sedation agent. Data collected included demographics, reason for methohexital use, dosing, type of procedure, success rate, adverse events (AE), duration of the procedure, and time to discharge. RESULTS: Methohexital was used in 240 patient encounters. Median age was 4years (IQR 2-7), 71.8% were male, and 80.4% were ASA-PS I or II. Indications for MHX use: egg+soy/peanut allergy in 93 (38.8%) and mitochondrial disorder 9 (3.8%). Median induction bolus was 2.1mg/kg (IQR, 1.9-2.8), median maintenance infusion was 4.5mg/kg/h (IQR, 3.0-6.0). Hiccups 15 (6.3%), secretions requiring intervention 14 (5.8%), and cough 12 (5.0%) were the most commonly occurring minor AEs. Airway obstruction was seen in 28 (11.6%). Overall success rate was 94%. Median time to discharge after procedure completion was 40.5min (IQR 28-57). CONCLUSION: Methohexital can be used with a high success rate and AEs that are not inconsistent with propofol administration. Methohexital should be considered when propofol is not a preferred option.


Subject(s)
Ambulatory Care , Anesthetics, Intravenous/administration & dosage , Methohexital/administration & dosage , Propofol/administration & dosage , Ambulatory Care/methods , Child , Child, Preschool , Dose-Response Relationship, Drug , Female , Humans , Male , Methohexital/pharmacology , Outpatients , Patient Selection , Practice Guidelines as Topic , Propofol/pharmacology , Retrospective Studies , United States
5.
Physiol Behav ; 154: 49-59, 2016 Feb 01.
Article in English | MEDLINE | ID: mdl-26548500

ABSTRACT

Carbohydrate intake, preference, and taste thresholds may be altered in current and former cigarette smokers, which may mediate weight gain and risk for obesity in individuals who quit smoking. Attempts to model these effects in rodents have primarily used noncontingent nicotine administration. The purpose of this research was to characterize changes in chow and sucrose intake in rats during a 23-h access model of i.v. nicotine self-administration (NSA), in which rats lever-pressed for chow, sucrose, and nicotine under concurrent fixed-ratio (FR) 1 schedules. Male rats were assigned to one of three groups that differed in food and drug availability. The Nicotine C+S group had concurrent access to nicotine, chow, and sucrose. The Saline C+S group had access to saline, chow, and sucrose. The Nicotine C-Only group had access to nicotine and chow, but not sucrose. Changes in food intake and weight gain were assessed during baseline, NSA, and nicotine withdrawal (i.e., saline extinction). Weight gain was significantly slowed during NSA and increased during withdrawal, but did not differ between the nicotine groups. NSA produced a significant decrease in both chow and sucrose intake. Gradual tolerance to nicotine's effects on sucrose, but not chow intake, occurred. During withdrawal, chow and sucrose intake increased, with a larger percent increase in sucrose intake compared to chow. The proportion of total food intake from sucrose was greater at the end of withdrawal compared to baseline, indicating a history of nicotine intake changed dietary preference. Combined, these results indicate that sucrose intake is more resistant to nicotine's appetite suppressant effects and withdrawal from nicotine produces a greater increase in sweet food intake alongside general increases in chow intake. Changes in overall food intake in current and ex-smokers may lead to increased risk for obesity and other health problems, potentially limiting the benefit of quitting smoking.


Subject(s)
Eating/drug effects , Feeding Behavior/drug effects , Food Preferences/drug effects , Nicotine/administration & dosage , Nicotinic Agonists/administration & dosage , Analysis of Variance , Anesthetics, Intravenous/pharmacology , Animals , Body Weight/drug effects , Conditioning, Operant/drug effects , Dose-Response Relationship, Drug , Extinction, Psychological/drug effects , Male , Methohexital/pharmacology , Rats , Reinforcement Schedule , Self Administration
6.
Psychiatry Res ; 215(2): 362-5, 2014 Feb 28.
Article in English | MEDLINE | ID: mdl-24388729

ABSTRACT

To assess the clinical utility of ketamine as an anesthetic agent for electroconvulsive therapy (ECT), based upon recent findings that ketamine may have antidepressant properties. Depressed ECT patients were randomly assigned to receive anesthesia with either ketamine or methohexital. Outcome measures included assessments of depressive severity, cognition, post-anesthesia side effects, and hemodynamics. Twenty one patients were treated with ketamine and 17 with methohexital. There were no significant differences in depression or cognitive outcomes between the two drugs. Additionally, there were no measures of post-anesthesia tolerability or hemodynamics which favored ketamine. Ketamine anesthesia does not accelerate the antidepressant effect of ECT or diminish the cognitive side effects, at least as measured in this study. Furthermore, there is no apparent benefit of ketamine for speed or quality of post-ECT recovery, and it is associated with higher systolic blood pressures after the treatments. Ketamine is associated with longer motor seizure duration than methohexital.


Subject(s)
Anesthetics/therapeutic use , Depressive Disorder, Major/therapy , Electroconvulsive Therapy/methods , Ketamine/therapeutic use , Methohexital/therapeutic use , Adult , Anesthetics/pharmacology , Blood Pressure/drug effects , Cognition/drug effects , Depressive Disorder, Major/drug therapy , Female , Hemodynamics/drug effects , Humans , Ketamine/pharmacology , Male , Methohexital/pharmacology , Middle Aged , Treatment Outcome
7.
Addict Biol ; 17(5): 887-96, 2012 Sep.
Article in English | MEDLINE | ID: mdl-21762288

ABSTRACT

A relatively small percentage of humans who are exposed to drugs of abuse eventually become addicted to or dependent on those drugs. These individual differences in likelihood of developing drug addiction may reflect behavioral, neurobiological or genetic correlates of drug addiction and are therefore important to model. Behavioral economic measures of demand establish functions whose overall elasticity (rate of decrease in consumption as price increases) reflects the reinforcing effectiveness of various stimuli, including drugs. Using these demand functions, we determined the reinforcing effectiveness of five drugs of abuse (cocaine, remifentanil, ketamine, methohexital and ethanol) in 10 rhesus monkeys with histories of intravenous drug-taking. There was a continuum of reinforcing effectiveness across the five drugs, with cocaine and remifentanil showing the most reinforcing effectiveness. There was also a continuum of sensitivity of the monkeys; two of the 10 animals, in particular, showed greater demand for the drugs than did the remaining eight monkeys. In addition, monkeys that demonstrated greater demand for one drug tended to show greater demand for all drugs but did not show a similar relatively greater demand for sucrose pellets. These findings suggest that the tendency to find drugs to be reinforcing is a general one, not restricted to particular drugs and also, that a minority of animals show a substantially enhanced sensitivity to the reinforcing effects of drugs. The possibility that differences in responsiveness to the reinforcing effects of drugs may form the basis of individual differences in drug-taking in humans should be considered.


Subject(s)
Individuality , Reinforcement, Psychology , Substance-Related Disorders/psychology , Anesthetics/pharmacology , Animals , Central Nervous System Depressants/pharmacology , Cocaine/pharmacology , Conditioning, Operant/drug effects , Ethanol/pharmacology , Female , Ketamine/pharmacology , Macaca mulatta , Male , Methohexital/pharmacology , Piperidines/pharmacology , Remifentanil
8.
World J Biol Psychiatry ; 11(2 Pt 2): 447-56, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19462341

ABSTRACT

BACKGROUND: Electroconvulsive therapy (ECT) is still considered the most effective biological treatment strategy in psychiatric disorders. However, the clinical efficacy of ECT may be affected by stimulus variables and the concomitant use of psychopharmacological medication. Furthermore, most anaesthetics have anticonvulsant properties and therefore might additionally influence the efficacy of ECT. METHOD: In order to explore whether different anaesthetics might alter the effectiveness or safety of ECT we retrospectively analyzed 5482 ECT treatments in 455 patients. Anaesthetics were chosen according to clinical reasons and comprised thiopental, methohexital, propofol and etomidate. RESULTS: Seizure duration was significantly affected by the anaesthetic medication with longest seizure activity during thiopental anaesthesia. In addition, postictal suppression, a further prospective parameter of ECT effectiveness, was significantly higher during propofol and thiopental anaesthesia. The clinical effectiveness was significantly better during propofol and thiopental anaesthesia. In contrast, the overall safety did not differ between the anaesthetic groups. CONCLUSION: Our study supports the hypothesis that inducting anaesthetic agents have a different impact on seizure duration, ictal and postictal electrophysiological indices and clinical efficacy of ECT. Compared to thiopental, which has been established as a standard anaesthetic during ECT, also the modern anaesthetic propofol is a suitable inducting agent.


Subject(s)
Anesthetics, Intravenous , Electroconvulsive Therapy/methods , Aged , Anesthesia, Intravenous , Anesthetics, Intravenous/pharmacology , Anesthetics, Intravenous/therapeutic use , Electroconvulsive Therapy/adverse effects , Electroencephalography/drug effects , Electromyography/drug effects , Etomidate/pharmacology , Etomidate/therapeutic use , Female , Humans , Male , Methohexital/pharmacology , Methohexital/therapeutic use , Middle Aged , Propofol/pharmacology , Propofol/therapeutic use , Retrospective Studies , Seizures/physiopathology , Thiopental/pharmacology , Thiopental/therapeutic use
9.
Seizure ; 18(9): 656-9, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19800265

ABSTRACT

INTRODUCTION: Methohexital has replaced amobarbital during Wada testing at many centers. The objective of our study was to compare the use of methohexital and amobarbital during Wada testing regarding language and memory lateralization quotients as well as speech arrest times. METHODS: A chart review of 582 consecutive patients undergoing 1041 Wada-procedures was performed (left=60, right=63, bilateral=459). Language lateralization was calculated based on duration of speech arrest using a laterality index, defined as (L-R)/(L+R). Memory lateralization was expressed as percentage of retained objects and laterality quotient. RESULTS: Language and memory lateralization revealed a similar distribution with amobarbital and methohexital. Speech arrest after left and right-sided injection was significantly longer in the amobarbital group as compared to the methohexital group. Language lateralization did not differ in the two groups. Percentage of retained memory items was higher in the methohexital group and there were fewer presented test items in the methohexital group. DISCUSSION: Language and memory testing during the Wada test can successfully be performed with methohexital instead of amobarbital. The shorter half-life of methohexital allows repeated injections and shorter interhemispheric testing intervals, but also shortens the testing window.


Subject(s)
Amobarbital/pharmacology , Anesthetics, Intravenous/pharmacology , Brain/drug effects , Hypnotics and Sedatives/pharmacology , Language Tests , Methohexital/pharmacology , Adolescent , Adult , Aged , Child , Functional Laterality/drug effects , Humans , Language , Memory/drug effects , Middle Aged , Young Adult
10.
Crit Care ; 13(5): R144, 2009.
Article in English | MEDLINE | ID: mdl-19737388

ABSTRACT

INTRODUCTION: The current debate about the side effects of induction agents, e.g. possible adrenal suppression through etomidate, emphasizes the relevance of choosing the correct induction agent in septic patients. However, cardiovascular depression is still the most prominent adverse effect of these agents, and might be especially hazardous in septic patients presenting with a biventricular cardiac dysfunction--or so-called septic cardiomyopathy. Therefore, we tested the dose-response direct cardiac effects of clinically available induction agents in an isolated septic rat heart model. METHODS: A polymicrobial sepsis was induced via cecal ligation and single puncture. Hearts (n = 50) were isolated and randomly assigned to five groups, each receiving etomidate, s(+)-ketamine, midazolam, propofol, or methohexitone at concentrations of 1 x 10-8 to 1 x 10-4 M. Left ventricular pressure, contractility and lusitropy, and coronary flow were measured. Cardiac work, myocardial oxygen delivery, oxygen consumption, and percentage of oxygen extraction were calculated. RESULTS: All of the induction agents tested showed a dose-dependent depression of cardiac work. Maximal cardiac work dysfunction occurred in the rank order of s(+)-ketamine (-6%)

Subject(s)
Analgesics/pharmacology , Anesthetics, Intravenous/pharmacology , Cardiomyopathies/chemically induced , Ketamine/pharmacology , Methohexital/pharmacology , Midazolam/pharmacology , Propofol/pharmacology , Sepsis/drug therapy , Analgesics/administration & dosage , Analgesics/adverse effects , Anesthetics, Intravenous/administration & dosage , Anesthetics, Intravenous/adverse effects , Animals , Cardiomyopathies/physiopathology , Dose-Response Relationship, Drug , Germany , Heart/drug effects , Ketamine/administration & dosage , Ketamine/adverse effects , Male , Methohexital/administration & dosage , Methohexital/adverse effects , Midazolam/administration & dosage , Midazolam/adverse effects , Propofol/administration & dosage , Propofol/adverse effects , Random Allocation , Rats , Rats, Wistar
11.
Brain Res ; 1294: 176-82, 2009 Oct 19.
Article in English | MEDLINE | ID: mdl-19646967

ABSTRACT

Thiopental is an anesthetic used for controlling high intracranial pressure (ICP) caused by brain surgery, brain trauma, and severe stroke. However, it remains controversial whether Thiopental is detrimental or beneficial in ischemic stroke. In this study, we used an animal model of ischemic stroke in spontaneously hypertensive rats to determine whether or not Thiopental is neuroprotective in the setting of brain ischemia. We observed that Thiopental caused a prolonged duration of unconsciousness with a high rate of mortality, that Thiopental created exaggerated neurological deficits that were revealed through limb placement tests at 4 days and 4 weeks after brain ischemia, and that infarct volume was increased in Thiopental-anesthetized rats. These data suggest that Thiopental is detrimental in ischemic stroke. Thus, our findings raise a caution about the use of Thiopental in the setting of ischemic stroke.


Subject(s)
Anesthetics, Intravenous/adverse effects , Brain Ischemia/drug therapy , Stroke/drug therapy , Thiopental/adverse effects , Anesthetics, Intravenous/pharmacology , Animals , Brain/drug effects , Brain/pathology , Brain Ischemia/mortality , Chloral Hydrate/adverse effects , Chloral Hydrate/pharmacology , Disease Models, Animal , Dyskinesia, Drug-Induced/mortality , Magnesium Sulfate/adverse effects , Magnesium Sulfate/pharmacology , Male , Methohexital/adverse effects , Methohexital/pharmacology , Pentobarbital/adverse effects , Pentobarbital/pharmacology , Random Allocation , Rats , Rats, Inbred SHR , Stroke/mortality , Thiopental/pharmacology , Time Factors , Treatment Outcome , Unconsciousness/chemically induced , Unconsciousness/mortality
12.
Infection ; 36(3): 220-5, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18454339

ABSTRACT

BACKGROUND: Barbiturates and propofol are used for deep sedation of patients with elevated intracranial pressure refractory to standard therapeutic regimens. Such patients often suffer from bacterial infections, which are most commonly caused by Staphylococcus aureus. Various interactions of anesthetics with components of the host defense have been documented, but very little is known about the influence on monocytes, which are a first-line defense against bacterial invasion. Therefore, we studied the effects of thiopental, methohexital, and propofol on monocyte phagocytosis using an in vitro whole blood model of viable S. aureus. MATERIALS AND METHODS: Whole blood samples were preincubated with different concentrations of thiopental, methohexital, and propofol. Phagocytosis was stopped at different time points after addition of viable S. aureus. Monocytes then were stained with monoclonal antibodies for flow cytometric analysis of monocyte recruitment (ratio of ingesting monocytes). Furthermore, the fluorescence intensity of ingested bacteria served as semiquantitative measurement of phagocytosis activity. RESULTS: Both barbiturates inhibited monocyte recruitment and phagocytosis activity concentration-dependently, whereas propofol did not affect any of the investigated parameters. At concentrations of 7.6 x10(-3) M thiopental or 1.1 x 10(-3) M methohexital and greater, monocyte recruitment and phagocytosis activity were significantly inhibited. The calculated half-maximum inhibitory concentration (IC50) of thiopental was 8.4 x 10(-3) M for monocyte recruitment and 8.6 x 10(-3) M for phagocytosis activity. The corresponding values for methohexital were 4.1 x 10(-3) M and 1.1 x 10(-3) M, respectively. CONCLUSION: The two barbiturates induce concentration-dependent inhibition of monocyte phagocytosis, whereas propofol is without effect. In combination with previously described effects on granulocyte function, these findings suggest that defense against bacterial infection might be reduced by barbiturates.


Subject(s)
Barbiturates/pharmacology , Monocytes/drug effects , Phagocytosis/drug effects , Propofol/pharmacology , Staphylococcus aureus/immunology , Adult , Flow Cytometry , Humans , Methohexital/pharmacology , Monocytes/immunology , Propofol/administration & dosage , Thiopental/pharmacology
14.
Acta Anaesthesiol Scand ; 50(2): 188-92, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16430540

ABSTRACT

BACKGROUND: Metohexital and propofol are short-acting induction agents, which have a tendency to prolong the QTc interval of the ECG. We studied whether this increase could be prevented by combining a beta-blocking agent, esmolol, with these drugs. Simultaneously, we studied the hemodynamic effects of these combinations. METHODS: In a randomized, double-blind study, 80 ASA I-II young adults were premedicated with oxycodone and atropin and allocated to one of four groups: propofol (P), propofol + esmolol (P + E), metohexital (E) or metohexital + esmolol (M + E). The doses were 2 mg/kg propofol/metohexital and 1 mg/kg esmolol. Alfentanil 15 microg/kg was used in all groups. The hemodynamic parameters were measured non-invasively and the electrocardiographic parameters using the signal processing method. RESULT: The highest QTc values, which often exceeded the normal upper limit of 440 ms, were recorded at the baseline or immediately after the administration of the induction drugs. The intervals were significantly shorter if esmolol was co-administered with either propofol or metohexital. The heart rate increased in the group M and decreased in the group P + E but remained unchanged in the groups P and M + E. Systolic and diastolic arterial pressures decreased during the study in all groups, most prominently in group P + E. CONCLUSIONS: During the anesthesia induction, the QTc interval was significantly shorter when esmolol was co-administered with either propofol or metohexital. The hemodynamic responses were properly controlled with the combination of metohexital and esmolol as well as with propofol alone, but the combination of propofol and esmolol tended to cause hemodynamic depression.


Subject(s)
Anesthesia, Intravenous/methods , Electrocardiography/drug effects , Hemodynamics/drug effects , Methohexital/pharmacology , Propanolamines/pharmacology , Propofol/pharmacology , Adolescent , Adrenergic beta-Antagonists/pharmacology , Adult , Analysis of Variance , Anesthetics, Intravenous/pharmacology , Blood Pressure/drug effects , Diastole/drug effects , Double-Blind Method , Drug Synergism , Heart Rate/drug effects , Humans , Middle Aged , Time Factors
15.
Crit Care Med ; 34(2): 478-83, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16424731

ABSTRACT

OBJECTIVE: Deep sedation with barbiturates or propofol is a standard therapy for patients with critically elevated intracranial pressure. Such patients are prone to infectious complications, especially to pneumonias, which are most commonly caused by Staphylococcus aureus. Although various immunomodulatory effects of barbiturates have been described in vitro, their influence on the phagocytosis of viable S. aureus has yet to be investigated. Therefore, we examined the effects of thiopentone, methohexitone, and propofol on the phagocytosis of viable S. aureus. DESIGN: Laboratory study. SETTING: University laboratory. PATIENTS: Ten healthy volunteers aged 32.5 +/- 7 yrs. INTERVENTIONS: Blood sampling. MEASUREMENTS AND MAIN RESULTS: Whole blood samples were preincubated with different concentrations of thiopentone, methohexitone, and propofol, which is an isopropylphenol derivate. After viable S. aureus was added, phagocytosis was stopped at different time points. Leukocytes were then stained with monoclonal antibodies for flow cytometric analysis of granulocyte recruitment (ratio of ingesting granulocytes) and phagocytosis activity (fluorescence intensity of ingested bacteria). Both barbiturates inhibited granulocyte recruitment and phagocytosis activity in a dose-dependent manner, whereas propofol did not affect any of the investigated variables. At concentrations higher than 7.6 x 10(-3) M (for thiopentone, p < .008) and 1.1 x 10(-3) M (for methohexitone, p < .04), granulocyte recruitment and phagocytosis activity were significantly inhibited. The calculated inhibitory concentrations (IC50) of thiopentone for granulocyte recruitment and for phagocytosis activity were 1.3 x 10(-2) M and 1.1 x 10(-2) M, respectively. The corresponding values for methohexitone were 3.6 x 10(-3) M and 1.1 x 10(-3) M. CONCLUSIONS: Our in vitro model points at substantially different effects of barbiturates and propofol on phagocytosis of S. aureus, which is one of the most important pathogens in patients who need neuroprotective therapy. The inhibitory effects of both barbiturates demonstrate a strong dose-dependency, with more pronounced effects for methohexitone. Impairment of phagocytosis activity was more pronounced than granulocyte recruitment.


Subject(s)
Anesthetics, Intravenous/pharmacology , Leukocytes/drug effects , Methohexital/pharmacology , Phagocytosis/drug effects , Propofol/pharmacology , Staphylococcus aureus/drug effects , Thiopental/pharmacology , Adult , Anesthetics, Intravenous/administration & dosage , Dose-Response Relationship, Drug , Flow Cytometry , Humans , Methohexital/administration & dosage , Propofol/administration & dosage , Staphylococcus aureus/metabolism , Thiopental/administration & dosage
16.
Int Immunopharmacol ; 6(1): 61-70, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16332514

ABSTRACT

FMLP stimulation of Xenopus oocytes expressing fMLP receptors leads to a concentration-dependent biphasic inward current. To identify the evolution of these currents we have examined the effects of blocking various cell signalling pathways. In addition we have analysed the effects of three intravenous anaesthetics on these fMLP-induced currents. Xenopus oocytes were microinjected with cRNA encoding the fMLP receptor and fMLP-stimulated (100 nM) currents measured, using two-electrode voltage-clamp (-70 mV), before and after injection of heparin (120 ng ml-1), wortmannin (1 microM), U73122 (5 microM) or buffer. Concentration-response curves were established for the action on fMLP-stimulated currents of thiopentone (5-500 microM), methohexitone (0.2-200 microM) and propofol (0.5-500 microM). Heparin significantly enhanced the fast current (p<0.05). Wortmannin had no effect on either current. U73122 inhibited only the slow current (p<0.05). All anaesthetics inhibited both currents, with the maximum inhibition for the fast/slow currents 70%/100%, 60%/60% and 100%/100% for thiopentone (IC50 147/120 microM), methohexitone (IC50 4.7/2.2 microM) and propofol (IC50 33/8 microM), respectively. We suggest (a) the slow current arises via the PLC/PKC pathway because it is reduced by the PLC inhibitor U73122, (b) the PI3K- and PLD-mediated pathways are not involved because wortmannin had no effect and (c) activation of the two conductance channels must be different because U73122 reduced the slow but not the fast current. Since both currents are decreased by all three anaesthetics, their inhibition might be mediated through an action at the agonist/receptor, although, since the slow current is consistently more sensitive than the fast, there may be additionally an action on cell signalling.


Subject(s)
Anesthetics, Intravenous/pharmacology , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Oocytes/drug effects , Animals , Female , Humans , In Vitro Techniques , Methohexital/pharmacology , Models, Biological , Oocytes/metabolism , Propofol/pharmacology , Protein Kinase C/metabolism , RNA, Complementary/administration & dosage , RNA, Complementary/genetics , Receptors, Formyl Peptide/genetics , Receptors, Formyl Peptide/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Signal Transduction/drug effects , Thiopental/pharmacology , Type C Phospholipases/metabolism , Xenopus laevis
17.
J Neurophysiol ; 94(1): 741-53, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15772241

ABSTRACT

During slow wave sleep and consummatory behaviors, electroencephalographic recordings from the rodent hippocampus reveal large amplitude potentials called sharp waves. The sharp waves originate from the CA3 circuitry and their generation is correlated with coherent discharges of CA3 pyramidal neurons and dependent on activities mediated by AMPA glutamate receptors. To model sharp waves in a relatively large hippocampal circuitry in vitro, we developed thick (1 mm) mouse hippocampal slices by separating the dentate gyrus from the CA2/CA1 areas while keeping the functional dentate gyrus-CA3-CA1 connections. We found that large amplitude (0.3-3 mV) sharp wave-like field potentials occurred spontaneously in the thick slices without extra ionic or pharmacological manipulation and they resemble closely electroencephalographic sharp waves with respect to waveform, regional initiation, pharmacological manipulations, and intracellular correlates. Through measuring tissue O2, K+, and synaptic and single cell activities, we verified that the sharp wave-like potentials are not a consequence of anoxia, nonspecific elevation of extracellular K+ and dissection-related tissue damage. Our data suggest that a subtle but crucial increase in the CA3 glutamatergic activity effectively recruits a population of neurons thus responsible for the generation of the sharp wave-like spontaneous field potentials in isolated hippocampal circuitry.


Subject(s)
Evoked Potentials/physiology , Extracellular Space/metabolism , Hippocampus/cytology , Membrane Potentials/physiology , Neurons/physiology , Analysis of Variance , Anesthetics/pharmacology , Animals , Animals, Newborn , Bicuculline/pharmacology , Chelating Agents/pharmacology , Dose-Response Relationship, Radiation , Drug Interactions , Egtazic Acid/pharmacology , Electric Stimulation/methods , Electrodes , Evoked Potentials/drug effects , Evoked Potentials/radiation effects , Excitatory Amino Acid Antagonists/pharmacology , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Excitatory Postsynaptic Potentials/radiation effects , GABA Antagonists/pharmacology , Hippocampus/physiology , Hypoxia/physiopathology , In Vitro Techniques , Membrane Potentials/drug effects , Membrane Potentials/radiation effects , Methohexital/pharmacology , Mice , Mice, Inbred C57BL , Neural Inhibition/drug effects , Neural Inhibition/physiology , Neural Inhibition/radiation effects , Neural Pathways/physiology , Neurons/classification , Neurons/drug effects , Oxygen/metabolism , Patch-Clamp Techniques/methods , Potassium/metabolism , Synaptic Transmission
18.
J Oral Maxillofac Surg ; 63(2): 215-9, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15690290

ABSTRACT

PURPOSE: Bispectral (BIS) analysis uses electroencephalogram information from a forehead electrode to calculate an index score (0 to 100; 0 = coma; 90 to 100 = awake). This index score correlates with the level of alertness in anesthetized patients. Classically, sedation has been monitored with clinical sedation scales such as the Observers Assessment of Alertness Sedation Scale (OAA/S), Modified Ramsey Scale, or a Visual Analog Scale (VAS). Our objective was to determine the correlation between clinical sedation scales and BIS index in pediatric patients undergoing sedation in an outpatient oral surgery setting. MATERIALS AND METHODS: Prospective cohort study of patients aged 2 to 17 years undergoing sedation in an outpatient oral surgery office. Sedation was performed in the customary manner with the addition of BIS monitoring. Three clinical sedation scores (OAA/S: 5 to 1; 5 = awake, 1 = unresponsive; Modified Ramsey: 1 to 6; 1-2 = awake, 6 = unresponsive; VAS: 0 to 10; 0 = awake, 10 = unresponsive) were assigned every 5 minutes by an investigator blinded to the BIS index. Data were analyzed using a repeated measures linear regression model. RESULTS: Sixteen subjects undergoing oral surgery, ages 4.5 years to 17 years, were enrolled, mean age 12.6 years +/- 4.3 years (standard deviation). Patients received methohexital in addition to 1 or more of the following: nitrous oxide, fentanyl, or midazolam. The results of the longitudinal regression analysis showed a highly significant association between the sedation scales and the BIS index. CONCLUSION: The BIS monitor may be a useful adjunct in monitoring pediatric patients receiving sedation in the outpatient setting.


Subject(s)
Anesthesia, Dental/methods , Conscious Sedation , Electroencephalography/drug effects , Monitoring, Intraoperative/methods , Adolescent , Ambulatory Surgical Procedures , Anesthetics, Inhalation , Anesthetics, Intravenous/pharmacology , Child , Child, Preschool , Cohort Studies , Consciousness/drug effects , Female , Fentanyl/pharmacology , Humans , Male , Methohexital/pharmacology , Midazolam/pharmacology , Nitrous Oxide/pharmacology , Oral Surgical Procedures , Prospective Studies , Signal Processing, Computer-Assisted , Single-Blind Method
19.
Acta Paediatr Taiwan ; 46(5): 294-300, 2005.
Article in English | MEDLINE | ID: mdl-16640004

ABSTRACT

Pediatric oncology/hematology patients, especially those with acute lymphoblastic leukemia (ALL), often undergo repeated painful invasive procedures. Deep sedation, mandatory for these procedures in young children, can reduce patient anxiety and get their compliance during procedures. This study assessed clinical experience of employing methohexital or thiamylal with midazolam as sedative for elective invasive procedures in children with ALL. Between November 1997 and March 2004, 20 out of 33 ALL children received deep sedation after evaluation, mainly because of relatively young age (mean age 4.60 +/- 2.03 years). A total of 176 procedures were done, with 139 being intrathecal therapy. There were 98 and 78 procedures for the methohexital and thiamylal groups, respectively. The average dosages to complete the procedures were 2.2 +/- 1.2 mg/kg for methohexital and 3.4 +/- 2.1 mg/kg for thiamylal. One out of the 176 procedures was failed due to bradycardia, hypotension and cyanosis, in the methohexital group. Otherwise, no significant adverse events were found. Increased heart rate (HR) during stable blood pressure (BP) was observed in both groups. In conclusion, under careful monitoring and performed by experienced practitioners, the application of methohexital or thiamylal combined with midazolam to achieve deep sedation for invasive procedures in young children with ALL is safe.


Subject(s)
Hypnotics and Sedatives/pharmacology , Methohexital/pharmacology , Midazolam/administration & dosage , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Thiamylal/administration & dosage , Blood Pressure/drug effects , Child , Child, Preschool , Electrocardiography , Female , Heart Rate/drug effects , Humans , Infant , Male , Retrospective Studies
20.
Psychopharmacology (Berl) ; 178(1): 83-91, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15322724

ABSTRACT

RATIONALE: There is disagreement in the literature with respect to how drugs of abuse affect the functioning of the hypothalamic-pituitary-adrenal (HPA) axis, and whether these changes in endocrine function may be related to the rewarding effects of these drugs. OBJECTIVES: To determine whether reinforcing drugs with different mechanisms of action affect HPA axis function at doses at which they serve as reinforcers. METHODS: Seven monkeys (6 male) were randomly assigned to self-administer methohexital-a barbiturate (n=4), midazolam-a benzodiazepine (n=3), or ethanol (n=5). Each monkey had a surgically implanted indwelling venous catheter, and was trained to respond on a fixed ratio of 30 lever presses to receive an injection of drug or saline. Blood samples were obtained before, during, and after the self-administration sessions for the measurement of ACTH and cortisol by radioimmunoassay. RESULTS: Although methohexital, midazolam, and ethanol all maintained self-administration behavior across a range of doses, they differed in their effects on ACTH and cortisol. Ethanol inhibited ACTH and cortisol secretion. Methohexital and midazolam both tended to decrease ACTH and cortisol at large doses, and increase these hormones at small doses, but the HPA effects of neither drug differed significantly from when saline was available. CONCLUSIONS: The neutral overall effect of methohexital and midazolam on HPA activity is consistent with other monkey and human studies, whereas the inhibitory effect of self-administered ethanol in the monkey contrasts with both the rat and human literature. The data in this study suggest that a change in HPA axis activity is not a requirement for drug-reinforced behavior in monkeys.


Subject(s)
Ethanol/pharmacology , Hypnotics and Sedatives/pharmacology , Hypothalamo-Hypophyseal System/drug effects , Methohexital/pharmacology , Midazolam/pharmacology , Pituitary-Adrenal System/drug effects , Adrenocorticotropic Hormone/blood , Adrenocorticotropic Hormone/metabolism , Animals , Conditioning, Operant , Dose-Response Relationship, Drug , Ethanol/administration & dosage , Female , Hydrocortisone/blood , Hydrocortisone/metabolism , Hypothalamo-Hypophyseal System/metabolism , Infusions, Intravenous , Macaca mulatta , Male , Methohexital/administration & dosage , Midazolam/administration & dosage , Pituitary-Adrenal System/metabolism , Radioimmunoassay , Reinforcement, Psychology , Self Administration
SELECTION OF CITATIONS
SEARCH DETAIL
...